---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-004874"
form_type: "8-K"
ticker: "PMCB"
cik: "0001157075"
company_name: "PharmaCyte Biotech, Inc."
filed_at: "2022-07-11T23:59:59+00:00"
generated_at: "2026-06-24T17:16:45.784258+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PharmaCyte Biotech reports FY2022 net loss of $4.2M; cash at $85.4M; authorizes $10M buyback

## Summary
- Cash and cash equivalents of $85.4M as of April 30, 2022; no debt mentioned.
- Net loss of ~$4.2M ($0.27 per share) compared to net loss of $3.6M ($2.45 per share) in prior year.
- Operating expenses increased to ~$4.4M from $3.6M, mainly due to Nasdaq listing and $90M capital raises.
- Board authorized up to $10M share repurchase program, to begin after release of preliminary results.
- CEO says company expects to begin two-phase pig study, the last major FDA requirement for phase 2b LAPC trial.

## SEC filing metadata
- accession: 0001683168-22-004874
- form_type: 8-K
- ticker: PMCB
- cik: 0001157075
- company_name: PharmaCyte Biotech, Inc.
- filed_at: 2022-07-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316822004874/0001683168-22-004874-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316822004874/pharmacyte_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-004874
- JSON: https://secwatch.observer/filing/0001683168-22-004874.json
- Plain text: https://secwatch.observer/filing/0001683168-22-004874.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.